Barclays
ABEO icon

Barclays’s Abeona Therapeutics ABEO Stock Holding History

Barclays’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-200
Closed -$85K – 6899
2017
Q3 		$85K Buy
+200
New +$53.7K ﹤0.01% 5031

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays's ABEO Position: Q1 2026 in Review

Barclays reduced its Abeona Therapeutics (ABEO) stake by 73% in Q1 2026, selling an estimated $360K and leaving 27,248 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #3941.

Barclays first reported a position in ABEO in Q2 2015 and has held it in 37 quarters since. The position peaked at $3.44M in Q3 2017. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

  • Barclays held 27,248 shares of Abeona Therapeutics worth $122K as of Q1 2026.
  • Barclays sold 72,063 Abeona Therapeutics shares in Q1 2026, an estimated $360K.
  • Abeona Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3941 holding.
  • Barclays first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 37 quarters since.
  • Barclays's Abeona Therapeutics position peaked at $3.44M in Q3 2017.
  • 108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.